清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

The CD38/CD3xCD28 Trispecific Antibody (SAR442257) Potentially Represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas

医学 抗体 T细胞 CD38 流式细胞术 细胞毒性T细胞 CD3型 单克隆抗体 癌症研究 CD28 免疫学 免疫系统 CD8型 生物 体外 川地34 生物化学 遗传学 干细胞
作者
Aurélie Dupuy,Laura Pelletier,Jérôme Giustiniani,Peter Kim,Kamlesh Kumar Bisht,Hongfang Wang,Helgi J. Van de Velde,Corinne Haïoun,Philippe Gaulard,Nicolás Ortonne
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 4384-4384 被引量:5
标识
DOI:10.1182/blood-2023-189088
摘要

Introduction Peripheral T-cell lymphomas (PTCL) remain an unmet medical need and novel therapeutic options inducing longstanding responses are needed. Immunotherapies with humanized monoclonal antibodies targeting cell surface receptors have dramatically improved the prognosis of many cancers. However, so far, only two antibodies targeting CCR4 and CD30 have been approved for the treatment of subsets of PTCL patients. Currently, several bi- and tri-specific antibodies are under pre-clinical or clinical evaluation to treat lymphomas. TSAR442257, a trispecific antibody (TriAb) which targets and binds CD38, CD3 and CD28 to engage T-cells against CD38-expressing tumor cells and enhance their CD3-triggered activation via CD28 co-stimulation. Here, we performed a preclinical investigation to evaluate the potential therapeutic value of the SAR442257 to treat PTCL, knowing that both CD28 and CD38 might represent targets in tumor T cells. Material and methodsCD28 and CD38 expression was studied in tumor cells of 268 PTCL patients. In situ semi-quantitative evaluation was done using immunohistochemistry on FFPE samples (n=250), and quantitative evaluation was performed using flow cytometry (FCM) on PBMCs (n=18) and PTCL lines (n=6). Multiplex immunofluorescence stainings with tumor cell marker were also performed on biopsies sections of selected cases. In vitro cytotoxic assays were performed by using 24h co-cultures of PTCL cell lines stained with a viability dye with allogeneic blood cells from healthy donors (HD) and SAR442257 or control TriAbs with null mutations in CD28 (D28), CD38 (D38) or both recognition domains at various concentrations (0-25000 pM) at 10:1 effector-to-target ratio. For primary PTCL cells, similar experiments were done with appropriate panels of surface markers aiming to identify tumor cells. Activation assays, measuring expression of CD25 and CD69, were done on PTCL lines and PBMCs from HD using the afore mentioned TriAbs at similar concentrations. ResultsWe found a recurrent but variable expression of CD28 and CD38 among the different PTCL entities (Figure 1). Overall, CD38 expression by tumor cells was found in 42% of PTCL samples in situ and 67% of PBMCs (ranging from 2.5% to 65%; data not shown). CD28 was found in neoplastic T cells in 56% of PTCL samples by IHC and 100% of PBMCs with a strong heterogeneity ranging from 30% to 99.4% (data not shown). CD38 and CD28 showed a range of expression among PTCL categories, with CD38 being more frequently expressed (Avg. IHC score: 250-300)) in PTCL diseases with a cytotoxic profile postulated to derive from innate immune/cytotoxic cells whereas CD28 was more frequently expressed (Avg. IHC score: 150-200) in PTCLs known to derive from helper T-cells (p<0.001, Figure 2). Co-expression of both targets was rare. Multiplex stainings confirmed co-expression of CD38 and/or CD28 targets in tumor cells but consistent with the FCM analysis, CD28 and CD38 were variably expressed in tumor T-cells of TFH PTCLs. The SAR442257 induced efficient killing of all CD28+/CD38+ and CD28-/CD38+ PTCL lines (with maximum killing reaching about 35%), while the D28 and D38 control TriAbs showed less efficient cytotoxic activities in six different cell lines. SAR442257 also induced CD25 and CD69 expression on normal T-cells suggesting efficient T-cell activation, (data not shown). Conclusion Altogether, this study shows that 1) most PTCL cells express at least CD28 or CD38, and 2) SAR442257 can efficiently kill malignant PTCL cells, while ensuring effective T-cell activation; In view of these results, clinical investigation of SAR442257 in PTCL is warranted.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
廖道罡完成签到,获得积分10
7秒前
专注寒蕾完成签到,获得积分10
9秒前
16秒前
H1lb2rt完成签到 ,获得积分10
23秒前
精明凝海发布了新的文献求助10
24秒前
wcl完成签到,获得积分10
31秒前
小黄完成签到 ,获得积分10
31秒前
精明的彩虹完成签到,获得积分10
32秒前
高高的玉兰完成签到,获得积分10
38秒前
43秒前
微笑妖丽完成签到,获得积分10
49秒前
qin完成签到 ,获得积分10
52秒前
mzhang2完成签到 ,获得积分10
1分钟前
wwwwwnnnnn完成签到 ,获得积分10
1分钟前
英俊的铭的应助被科研通管家采纳,获得10
1分钟前
1分钟前
沙海沉戈完成签到,获得积分0
1分钟前
彩色听筠完成签到,获得积分10
1分钟前
复杂的雁芙完成签到,获得积分10
1分钟前
领导范儿的应助被BYL采纳,获得10
1分钟前
1分钟前
成就云朵完成签到,获得积分10
1分钟前
1分钟前
晓晓完成签到,获得积分10
2分钟前
晓晓发布了新的文献求助10
2分钟前
lulu完成签到,获得积分10
2分钟前
韦韦完成签到 ,获得积分10
2分钟前
李木禾完成签到 ,获得积分10
2分钟前
vbnn完成签到 ,获得积分10
2分钟前
2分钟前
Husile发布了新的文献求助10
2分钟前
迷人悒完成签到,获得积分10
2分钟前
huluwa完成签到,获得积分10
2分钟前
2分钟前
YZY完成签到 ,获得积分10
2分钟前
2分钟前
坚强冷荷完成签到,获得积分10
2分钟前
风中碧菡完成签到,获得积分10
2分钟前
BYL发布了新的文献求助10
2分钟前
Husile完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179980
求助须知:如何正确求助?哪些是违规求助? 9570196
关于积分的说明 21808506
捐赠科研通 7775966
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557389
邀请新用户注册赠送积分活动 2478998